Popular Articles

Opinion: Governments Must Take 'Concrete Action' To Reduce Maternal Mortality, Morbidity
With the U.N. Human Rights Council"s June session coming up, governments have a "chance to prove that they value women"s lives by taking concrete action" to recognize "preventable maternal death as a violation of women"s rights," Mary Robinson and Alicia Yamin, advisory council members of the International Initiative on Maternal Mortality and Human Rights, write in a Boston Globe opinion piece.
pharmacy online Dentisti fiume
Estrogens Do Not Protect Against Cardiovascular Death For Transsexuals
Long-term estrogen use does not protect male-to-female transsexuals from death due to cardiovascular disease but does not appear to raise their overall death rate, a new study found. The results were presented at The Endocrine Society"s 91st Annual Meeting in Washington, D.C.
News of the day
Reducing Medical Residents' Hours Would Cost $2.5B Annually, Study Says
Implementing proposed reductions in the number of hours medical residents work could cost as much as $2.5 billion annually, according to a recent study published in the New England Journal of Medicine, the Baltimore Sun reports. The study follows an Institute of Medicine report that proposed reducing the maximum hours that residents can work without sleep from 30 to 16, increasing the number of days they must take off and improving their supervision (Desmon, Baltimore Sun, 5/21). In 2003, the Accreditation Council for Graduate Medical Education reduced the number of hours residents at teaching hospitals could work weekly from more than 100 hours to 80 hours. In the recent study, which was partially funded by IOM, researchers examined post-2003 literature on resident work hours and patient harm and evaluated it against additional labor costs. The authors concluded that the IOM recommendations "would be costly, and their effectiveness is unknown" (Shishkin, Wall Street Journal, 5/21). Teryl Nuckols, the lead author of the study, said that teaching hospitals would most likely need to hire more residents and experienced physicians to take care of patients, which would likely cost each teaching hospital $3.2 million annually (Baltimore Sun, 5/21). The study was accompanied by an NEJM editorial in which the authors "strongly disagree" with the IOM recommendations, claiming that reducing resident work hours "leads to an increase in the number of handoffs in care, and this increase outweighs the potential benefits of reducing residents" fatigue." The accreditation council said that more research is needed before it decides whether to adopt the IOM recommendations. The council"s decision will be announced in February 2010 (Wall Street Journal, 5/21).
Health Insurance

New Small And Medium Sized Enterprises Join TI Pharma By Signing Two New Projects

Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget of nearly 6 million euros. The new consortium, formed by Syncom, Synvolux Therapeutics, and University Medical Center Groningen, focuses on designing a versatile drug delivery system for inflammatory diseases and cancer. Another new consortium is formed by InteRNA Technologies, Utrecht University and VU University Medical Center, and focuses on the development of anti-angiogenic microRNA-based therapeutic products for the treatment of cancer. Versatile drug delivery platform for inflammatory diseases and cancer New molecular entities (NMEs) in the drug development pipeline comprise various classes of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation might circumvent side effects and improve their general therapeutic efficacy. However, currently, no appropriate formulation technology is available for these kinase inhibitors. This project focuses on a systematic approach in which chemical modification of NMEs is combined with drug formulation studies. This will lead to a versatile drug delivery platform for future clinical application of kinase inhibitors in the treatment of cancer and chronic inflammatory diseases. "This approach is expected to make targeted drug delivery finally meet its expectations, as it will become available for a variety of drug classes that are under development in the pharmaceutical industry," according to the consortium members. Development of novel anti-angiogenic miRNA based therapeutics "Conventional cancer treatment such as surgery, radiation therapy and chemotherapy are far from sufficient, therefore, new strategies of cancer treatment are needed more than ever," says Roel Schaapveld, Chief Executive Officer, InteRNA. There is a large body of evidence indicating that tumor growth and metastasis formation are dependent on the formation of new blood vessels. Furthermore, angiogenesis is an early event in the development of tumors, being already switched on in pre-cancerous events and long before visible or clinically relevant tumor mass is present. Schaapveld: "These two features make angiogenesis an ideal target for the development of novel anti-cancer strategies." The recent discovery that non-coding RNAs, called microRNAs (miRNAs), play a critical role in gene regulation provides new opportunities to discover RNAs that can control angiogenesis. The major aim of this project is to establish a technology platform for the development of (anti-cancer) therapeutics based on angiostatic miRNAs. miRNA is utilized as a therapeutic modality and advanced nanoparticle delivery systems accomplish intracellular delivery of nucleic acid agents. These will be combined with the identification of surface receptor targets on tumor blood vessels to allow for therapeutic intervention. Eventually, this will result in the development of anti-angiogenic miRNA-based therapeutic products for the treatment of cancer. TI Pharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):